Viewing Study NCT02220712


Ignite Creation Date: 2025-12-26 @ 11:10 AM
Ignite Modification Date: 2025-12-29 @ 6:45 PM
Study NCT ID: NCT02220712
Status: COMPLETED
Last Update Posted: 2021-01-25
First Post: 2014-08-18
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Organization:

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2021-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
JapicCTI-142635 OTHER Japic View